On January 13, 2025, Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, released its financial report for the fourth quarter and full year 2024. The company reported that its ARCALYST net product revenue amounted to $121.9 million for the fourth quarter and $416.4 million for the full year 2024, representing significant growth. Additionally, Kiniksa disclosed that as of December 31, 2024, it had $243.6 million in cash, cash equivalents, and short-term investments.
The company provided guidance for 2025, with ARCALYST net product revenue expected to range between $560 million and $580 million. Kiniksa highlighted the growing uptake of ARCALYST in recurrent pericarditis, with approximately 13% of the target patient population actively on the therapy by the end of 2024.
Kiniksa Pharmaceuticals is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, further showcasing its progress and future prospects. The company’s focus remains on developing immune-modulating assets to target cardiovascular and autoimmune diseases, with a strong emphasis on differentiation and patient care.
For more information about Kiniksa Pharmaceuticals and its products, individuals can visit the company’s website. The firm’s flagship product, ARCALYST, has shown promise in treating various conditions, including recurrent pericarditis and Cryopyrin-Associated Periodic Syndromes (CAPS), among others.
Nevertheless, like all public disclosures, forward-looking statements can be subject to risks and uncertainties, and actual results may differ from the expectations. Kiniksa Pharmaceuticals encourages individuals to refer to regulatory filings for a comprehensive understanding of potential risks and factors affecting the company.
The trademark ARCALYST is owned by Regeneron Pharmaceuticals, Inc. Kiniksa Investors can reach out to Jonathan Kirshenbaum at (781) 829-3949, while media inquiries may be directed to Tyler Gagnon at (781) 431-9100.
It’s clear that Kiniksa Pharmaceuticals remains steadfast in its mission to provide innovative solutions for underserved patient populations, as evidenced by its strong financial performance and future revenue projections.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Kiniksa Pharmaceuticals’s 8K filing here.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals
- What Are Dividend Challengers?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Use the MarketBeat Dividend Calculator
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 01/13 – 01/17
